anordrin: RN given refers to (2beta,5alpha,17alpha)-isomer; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 6917889 |
| SCHEMBL ID | 18906509 |
| MeSH ID | M0056713 |
| Synonym |
|---|
| af-53 |
| alpha-anordrin |
| anordrin |
| 2-epsilon,17-alpha-diethynyl, a-nor-androstane-2-epsilon, 17-beta-dihydroxydipropinate |
| a-norpregn-20-yne-2,17-diol, 2-ethynyl-, dipropanoate, (2beta,5alpha,17alpha)- |
| a-norpregn-20-yne-2,17-diol, 2-ethynyl-, dipropanoate, (2-beta,5-alpha,17-alpha)- |
| dicyclopenta(a,f)naphthalene-1,7-diol, 1,7-diethynylhexadecahydro-8a,10a-dimethyl-, dipropanoate, (1r,3as,3br,5as,7r,8as,8bs,10as)- |
| 2-alpha,17-alpha-diethynyl-a-nor-5-alpha-androstane-2-beta,17-beta-diol dipropionate |
| dicyclopenta(a,f)naphthalene-1,7-diol, 1,7-diethynylhexadecahydro-8a,10a-dimethyl-, dipropanoate, (1r-(1alpha,3abeta,3balpha,5abeta,7alpha,8aalpha,8bbeta,10aalpha))- |
| 2,17alpha-diethynyl-a-norandrostane-2,17beta-dihydroxydipropionate |
| [(2r,3as,3bs,5as,6r,8as,8br,10as)-2,6-diethynyl-3a,5a-dimethyl-2-propanoyloxy-1,3,3b,4,5,7,8,8a,8b,9,10,10a-dodecahydroindeno[5,4-e]inden-6-yl] propanoate |
| 6r25f2a061 , |
| 56470-64-5 |
| unii-6r25f2a061 |
| .alpha.-anordrin |
| anordrin [who-dd] |
| a-norpregn-20-yne-2,17-diol, 2-ethynyl-, dipropanoate, (2.beta.,5.alpha.,17.alpha.)- |
| DTXSID40872682 |
| SCHEMBL18906509 |
| Q25091495 |
Anordrin is a convenient, safe and effective oral contraceptive drug.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Thus Anordrin is a convenient, safe and effective oral contraceptive drug." | ( Pharmacological studies of a contraceptive drug anordrin. Chih-ping, K; Hsiu-chüan, C; Kang, T; Ming-kang, C; Shih-hsing, C; Ta-wei, P, ) | 0.84 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Anordrin has been used as an effective postcoital contraceptive in China. " | ( Effects of anordrin and its analogue on antifertility. Chen, BL; Dai, MZ; Liu, CQ; Shen, SR; Zhang, GZ, 1985) | 2.1 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Anordrin appears to inhibit follicular development when given during the stage of follicular recruitment." | ( Antiovulatory action of anordrin in the cynomolgus monkey (Macaca fascicularis). Chatterton, RT; Mehta, RR, 1991) | 1.31 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The results confirmed the usefulness of this method for characterizing the pharmacokinetic profiles of ACP and its major metabolite M2 in a Phase I pharmacokinetic study." | ( Direct quantification of anorethidrani disuccinate and determination of sterol metabolites by chemical derivatization combined with LC-MS/MS: Application to a Phase I pharmacokinetic study in humans. Chen, X; Chen, Y; Jiang, J; Li, L; Lu, Y; Zhong, D, 2020) | 0.56 |
Mifepristone alone or in combination with anordrin given orally within 96 hours after unprotected intercourse as an emergency contraceptive.
| Excerpt | Reference | Relevance |
|---|---|---|
| "5 mg/kg combined with anordrin 2 mg/kg when given on d 6-8 of pregnancy." | ( [Antifertility effects of RU-486 in combination with anordrin in rats]. Lin, ZM; Liu, GM; Qian, YX; Shen, PJ; Shen, QC; Xu, RY, 1989) | 0.84 |
| "In view of the unexpected ability of anordrin to synergize with RU 486 in terminating pregnancy, it was pertinent to examine the actions of the dihydroxylated metabolite of anordrin, anordiol, alone and in combination with RU 486." | ( Anordiol is more potent than anordrin for terminating pregnancy when administered with RU 486. Bardin, CW; Chang, CC; Wang, WC, 1993) | 0.85 |
| "To investigate the effectiveness and side-effects of different doses of mifepristone alone or in combination with anordrin given orally within 96 hours after unprotected intercourse as an emergency contraceptive." | ( [A randomized multicentre clinical trial on different doses of mifepristone alone and in combination with anordrin as emergency contraception]. Sang, G; Shao, Q; Zhang, L, 1999) | 0.73 |
| " Two groups received mifepristone in combination with anordrin showed significant lower incidence of withdrawal bleeding than those in mifepristone alone groups." | ( [A randomized multicentre clinical trial on different doses of mifepristone alone and in combination with anordrin as emergency contraception]. Sang, G; Shao, Q; Zhang, L, 1999) | 0.77 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 21 (47.73) | 18.7374 |
| 1990's | 19 (43.18) | 18.2507 |
| 2000's | 1 (2.27) | 29.6817 |
| 2010's | 2 (4.55) | 24.3611 |
| 2020's | 1 (2.27) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (18.05) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 3 (6.67%) | 5.53% |
| Reviews | 1 (2.22%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 41 (91.11%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||